Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

NCT05912816 PHASE2 RECRUITING

This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients . The study was conducted in accordance with the Good Practice for Quality Control of Clinical Trials for Pharmaceutical Products (GCP). Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (2.0 mg/kg intravenously every 3 weeks) combined with Tislelizumab (200mg intravenously every 3 weeks).

Details

Lead sponsor	RenJi Hospital
Phase	PHASE2
Status	RECRUITING
Enrolment	20
Start date	Sat Jun 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Upper Urinary Tract Urothelial Carcinoma
• Kidney Preservation
• HER-2 ADC
• PD-1antibody

Interventions

• RC48 Combined With Tislelizumab

Countries

China